April 24, 2020
– GlycoMimetics reports Q1 2020 results on May 1
ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: GlycoMimetics
April 6, 2020
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved…
May 2, 2019
GlycoMimetics ends first quarter 2019 with $195.6 million cash
Enrolled first patient in National Cancer Institute (NCI)-sponsoredPhase 3 trial of uproleselan in older adults with previously untreatedacute myeloid leukemia (AML)
April 29, 2019
GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel
Eric Feldman, M.D.,a specialist in leukemia and bone marrow disorder therapies, has beenappointed Vice President of Clinical Development GlycoMimetics.
April 22, 2019
GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359
Preclinical studies indicatethat targeting both E-selectin and CXCR4 with a single compound couldimprove efficacy in the treatment of cancers that involve the bonemarrow such as AML and multiple myeloma or in solid tumors thatmetastasize to the bone, such as prostate cancer and breast cancer.
April 4, 2019
GlycoMimetics to Present at Upcoming Investor Conferences
ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that senior management will present corporate updates at two upcoming investor conferences…